MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
15.95
-1.03 (-6.07%)
At close: Mar 28, 2025, 4:00 PM
15.84
-0.11 (-0.69%)
After-hours: Mar 28, 2025, 5:52 PM EDT
Company Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally.
It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.
MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd.
Country | Israel |
Founded | 2000 |
IPO Date | Mar 20, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 111 |
CEO | Ofer Gonen |
Contact Details
Address: 42 Hayarkon Street Yavne, 8122745 Israel | |
Phone | 972 7 797 14100 |
Website | mediwound.com |
Stock Details
Ticker Symbol | MDWD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001593984 |
CUSIP Number | M68830104 |
ISIN Number | IL0011316309 |
SIC Code | 2833 |
Key Executives
Name | Position |
---|---|
Ofer Gonen B.Sc. | Chief Executive Officer |
Hani Luxenburg | Chief Financial Officer |
Dr. Shmulik Hess Ph.D. | Chief Operating Officer and Chief Commercial Officer |
Yaron Meyer Adv. | Executive Vice President, General Counsel and Corporate Secretary |
Dr. Ety Klinger MBA, Ph.D. | Chief Research and Development Officer |
Dr. Lior Rosenberg M.D. | Co-Founder |
Dr. Liron Gal | Executive Director of Manufacturing Science and Technology |
Barry J. Wolfenson | Executive Vice President of Strategy and Corporate Development |
Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2025 | 424B3 | Prospectus |
Mar 27, 2025 | EFFECT | Notice of Effectiveness |
Mar 19, 2025 | F-3 | Filing |
Mar 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 19, 2025 | 20-F | Annual and transition report of foreign private issuers |
Mar 19, 2025 | 6-K | Report of foreign issuer |
Feb 12, 2025 | 6-K | Report of foreign issuer |
Feb 11, 2025 | SCHEDULE 13G/A | Filing |
Jan 8, 2025 | 6-K | Report of foreign issuer |
Dec 19, 2024 | 6-K | Report of foreign issuer |